Vitreofoveal Traction Associated With Pilocarpine for Presbyopia

Ophthalmic Surg Lasers Imaging Retina. 2022 Jul;53(7):410-411. doi: 10.3928/23258160-20220629-01. Epub 2022 Jul 1.


Vuity (pilocarpine HCL ophthalmic 1.25%) was approved for the treatment of presbyopia in October 2021. Previous case series have reported the presence of vitreofoveal traction and retinal detachment following pilocarpine administration, but this was not reported in the recent randomized control trials assessing the efficacy of Vuity. The authors report a case of a woman of 65 years who developed vitreomacular traction immediately following the first administration of Vuity, review the literature, and present considerations regarding screening and management of patients starting Vuity. [Ophthalmic Surg Lasers Imaging Retina 2022; 53:410-411.].

Publication types

  • Case Reports

MeSH terms

  • Female
  • Humans
  • Pilocarpine / adverse effects
  • Presbyopia*
  • Retinal Diseases* / diagnosis
  • Tomography, Optical Coherence
  • Traction
  • Vitreous Detachment* / diagnosis


  • Pilocarpine